For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com
Daiichi Sankyo Announces Establishment of DAIICHI SANKYO VIETNAM COMPANY LIMITED
TTOKYO, Japan (September 24, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the establishment of DAIICHI SANKYO VIETNAM COMPANY LIMITED, (hereafter, Daiichi Sankyo Vietnam) as a wholly owned subsidiary as of September 18, 2020.
Daiichi Sankyo established a representative office in Ho Chi Minh City, Vietnam, in 2014, to provide support activities for the sale and promotion of its pharmaceutical products, such as Cravit®. In order to better respond to the changing business environment of the pharmaceutical industry in Vietnam and to strengthen its business operations, focusing on forthcoming products, Daiichi Sankyo has established a local legal entity to conduct sales activities.
Daiichi Sankyo will strive to further enhance its business platform in Asia while contributing to the healthcare in the country through Daiichi Sankyo Vietnam.
[Corporate Profile of New Subsidiary in Vietnam]
1）Corporate Name: DAIICHI SANKYO VIETNAM COMPANY LIMITED
2）Date of Establishment: September 18, 2020
3）Legal Representative: Yukinori Tominaga (General Director)
4）Business Category: Wholesale of household goods etc.
5）Capital: USD $8 million
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.